As a result, Trenbolone Acetate now functions as the primary anabolic compound (aka the ‘workhorse’ compound) that will function to provide the muscle growth throughout the cycle. Trenbolone is strictly an advanced level anabolic steroid, unfit for use by beginners of any type. In this cycle, the Acetate variant of Trenbolone is utilized simply due to its seamless compatibility with Testosterone Propionate. This is because the Propionate and Acetate esters as, previously mentioned early on in this section of the profile, both possess almost identical half-lives (3 days for Trenbolone Acetate and days for Testosterone Propionate). This therefore provides an ease of convenience for the user, as well as smoother injection and administration frequencies. The fact that Testosterone is being utilized at a low enough doses to avoid aromatization, combined with the fact that Trenbolone’s inability to convert into Estrogen at any dose should result in the total elimination of any potential water retention, bloating, gynecomastia or any side effects associated with Estrogen . It is important to note that this cycle in particular is strong enough to be utilized as a bulking cycle, lean mass cycle, or cutting cycle – all without the inflated potential for water retention or other Estrogenic side effects.
Although patients receiving systemic corticosteroid therapy are more susceptible to secondary infection than patients not receiving corticosteroids, administration via the inhaled route minimizes this risk. Corticosteroid therapy can mask the symptoms of infection and should not be used in cases of bacterial, fungal, or viral infections that are not adequately controlled by anti-infective agents, except in life-threatening circumstances. Fluticasone; salmeterol should be avoided in patients with tuberculosis infections of the respiratory tract if possible. The incidence or course of acute bacterial or viral infection is probably minimally affected by inhaled corticosteroids in immunocompetent individuals; however, close monitoring of patients with immunosuppression is recommended if treatment with an inhaled corticosteroid is necessary.
Initial dose based on previous asthma drug therapy and disease severity; 100 mcg via oral inhalation once daily is the usual recommended starting dose for patients not on an inhaled corticosteroid. After 2 weeks of therapy, if asthma symptoms are uncontrolled, increase dose to 200 mcg via oral inhalation once daily. Max: 200 mcg once daily. Administer at the same time each day. The maximum beneficial effect may not be achieved for up to 2 weeks or longer after starting treatment. Titrate to the lowest effective dose once asthma stability is achieved.